P. Yu

发表

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Wei Xu, J. Nuss, Wentao Zhang, 2012, Bioorganic & medicinal chemistry letters.

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

J. Martini, J. Nuss, Wentao Zhang, 2012, Bioorganic & medicinal chemistry letters.

Discovery of XL413, a potent and selective CDC7 inhibitor.

Wei Xu, Charles R. Holst, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

The Novel Bacterial N-Demethylase PdmAB Is Responsible for the Initial Step of N,N-Dimethyl-Substituted Phenylurea Herbicide Degradation

Chaoyang Zhou, Xin Yan, Ji Zhang, 2013, Applied and Environmental Microbiology.

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

K. Yamaguchi, D. J. Matthews, F. Yakes, 2014, Molecular Cancer Therapeutics.

Protocol to prepare functional cellular nanovesicles with PD1 and TRAIL to boost antitumor response

Xiaolong Liu, Ming Wu, Cuilin Zhang, 2021, STAR protocols.

Abstract B269: Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET

J. Li, Lora Zhao, V. Vysotskaia, 2009 .

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Yongchang Shi, Yu-Chien Chou, K. Yamaguchi, 2011, Molecular Cancer Therapeutics.

N. Munshi, J. Braverman, T. Campbell, 2021, Blood advances.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

F. Yakes, A. Joly, Lora Zhao, 2013, Thyroid : official journal of the American Thyroid Association.

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

J. Martini, J. Nuss, Joerg Bussenius, 2012, ACS medicinal chemistry letters.

Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients

Chuan-Fa Chang, Shih-Yun Guu, P. Yu, 2017, PloS one.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

K. Yamaguchi, D. J. Matthews, F. Yakes, 2015, Molecular Cancer Therapeutics.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

K. Yamaguchi, J. Greshock, R. Wooster, 2009, Cancer research.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.

Charles R. Holst, J. Nuss, Xiang Wu, 2012, Journal of medicinal chemistry.

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

F. Yakes, A. Joly, J. Martini, 2007, Clinical Cancer Research.

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

Wei Xu, Wei Cheng, F. Yakes, 2012, Bioorganic & medicinal chemistry letters.

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

M. Belvin, J. Ware, K. Hoeflich, 2012, Clinical Cancer Research.

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

K. Leong, J. Hsu, P. Lamb, 2022, Molecular cancer therapeutics.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial

H. Döhner, H. Dombret, B. Skikne, 2021, Haematologica.

RBC Membrane Camouflaged Semiconducting Polymer Nanoparticles for Near-Infrared Photoacoustic Imaging and Photothermal Therapy

Zuwu Wei, Ming Wu, P. Yu, 2020, Nano-Micro Letters.

RBC Membrane Camouflaged Semiconducting Polymer Nanoparticles for Near-Infrared Photoacoustic Imaging and Photothermal Therapy

Xiaolong Liu, C. Zhong, Zuwu Wei, 2020, Nano-micro letters.

Converting Immune Cold into Hot by Biosynthetic Functional Vesicles to Boost Systematic Antitumor Immunity

Zuwu Wei, Jingfeng Liu, Xiaolong Liu, 2020, iScience.

E. Neufeld, M. Cappellini, V. Viprakasit, 2020 .

Nanoplatform Self‐Assembly from Small Molecules of Porphyrin Derivatives for NIR‐II Fluorescence Imaging Guided Photothermal‐Immunotherapy

Xiaolong Liu, Lixia Yang, Yongyi Zeng, 2021, Advanced healthcare materials.

Preclinical Development Cabozantinib ( XL 184 ) , a Novel MET and VEGFR 2 Inhibitor , Simultaneously Suppresses Metastasis , Angiogenesis , and Tumor Growth

K. Yamaguchi, J. Lesch, F. Yakes, 2011 .

Clinical observation of Yiqi Qingdu prescription on the treatment of intermediate-stage and advanced non-small-cell lung cancer.

Xiaoling Tang, P. Yu, Q. Liang, 2021, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

Genetically Engineered Nanovesicles Mobilize Synergistic Antitumor Immunity by ADAR1 Silence and PDL1 Blockade.

Xiaolong Liu, Yongyi Zeng, Ming Wu, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

Facile phase transfer of hydrophobic Fe3O4@Cu2-xS nanoparticles by red blood cell membrane for MRI and phototherapy in the second near-infrared window.

Ke-can Lin, Hui Liu, Yanan Xue, 2020, Journal of materials chemistry. B.

E. Neufeld, M. Cappellini, V. Viprakasit, 2023, European journal of haematology.

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

K. Yamaguchi, F. Yakes, A. Joly, 2011, Molecular Cancer Therapeutics.

XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile

P. Lamb, C. Scheffold, P. Yu, 2020 .